Sonoma Pharmaceuticals, Inc. (SNOA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNOA Stock Summary
- SONOMA PHARMACEUTICALS INC's market capitalization of $5,306,082 is ahead of only 1.04% of US-listed equities.
- With a year-over-year growth in debt of -47.91%, SONOMA PHARMACEUTICALS INC's debt growth rate surpasses just 5.78% of about US stocks.
- As for revenue growth, note that SNOA's revenue has grown -13.82% over the past 12 months; that beats the revenue growth of just 10.96% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to SONOMA PHARMACEUTICALS INC, a group of peers worth examining would be LGL, NVFY, PFSW, NAII, and IIIN.
- Visit SNOA's SEC page to see the company's official filings. To visit the company's web site, go to www.sonomapharma.com.
SNOA Valuation Summary
- In comparison to the median Healthcare stock, SNOA's EV/EBIT ratio is 105.81% lower, now standing at -0.5.
- Over the past 193 months, SNOA's price/sales ratio has gone down 23.8.
Below are key valuation metrics over time for SNOA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SNOA | 2022-11-25 | 0.4 | 0.8 | -1.0 | -0.5 |
| SNOA | 2022-11-23 | 0.4 | 0.7 | -0.9 | -0.4 |
| SNOA | 2022-11-22 | 0.4 | 0.8 | -0.9 | -0.4 |
| SNOA | 2022-11-21 | 0.5 | 0.8 | -1.0 | -0.5 |
| SNOA | 2022-11-18 | 0.5 | 1.0 | -1.2 | -0.7 |
| SNOA | 2022-11-17 | 0.5 | 0.9 | -1.1 | -0.7 |
SNOA Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -28.76%.
- Its 4 year net cashflow from operations growth rate is now at 36.18%.
- The 5 year cash and equivalents growth rate now stands at -81.98%.
The table below shows SNOA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 12.514 | -5.084 | -5.792 |
| 2022-06-30 | 12.927 | -4.558 | -4.875 |
| 2022-03-31 | 12.628 | -4.248 | -5.086 |
| 2021-12-31 | 12.487 | -4.329 | -5.802 |
| 2021-09-30 | 14.521 | -3.257 | -5.508 |
| 2021-06-30 | 16.546 | -2.31 | -5.288 |
SNOA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SNOA has a Quality Grade of D, ranking ahead of 19.4% of graded US stocks.
- SNOA's asset turnover comes in at 1.011 -- ranking 24th of 682 Pharmaceutical Products stocks.
- AGLE, REGN, and NAVB are the stocks whose asset turnover ratios are most correlated with SNOA.
The table below shows SNOA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.011 | 0.348 | -0.457 |
| 2021-03-31 | 1.064 | 0.352 | -0.307 |
| 2020-12-31 | 1.210 | 0.393 | -0.153 |
| 2020-09-30 | 1.226 | 0.405 | -0.202 |
| 2020-06-30 | 1.214 | 0.411 | -0.353 |
| 2020-06-30 | 1.305 | 0.416 | -0.272 |
SNOA Stock Price Chart Interactive Chart >
SNOA Price/Volume Stats
| Current price | $1.67 | 52-week high | $5.12 |
| Prev. close | $1.71 | 52-week low | $1.58 |
| Day low | $1.63 | Volume | 25,800 |
| Day high | $1.74 | Avg. volume | 542,290 |
| 50-day MA | $2.02 | Dividend yield | N/A |
| 200-day MA | $2.85 | Market Cap | 5.18M |
Sonoma Pharmaceuticals, Inc. (SNOA) Company Bio
Sonoma Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. Sonoma Pharmaceuticals serves customers worldwide.
Latest SNOA News From Around the Web
Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2023 Results Key Financial Results Revenue: US$3.33m (down 11... |
Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its second fiscal quarter and six months ended September 30, 2022. |
Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United StatesSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for |
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, GermanySonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, announced that it will be exhibiting at the CPHI Conference in Frankfurt, Germany on November 1-3, 2022. |
Sonoma Pharmaceuticals Reports First Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, today announced financial results for its first fiscal quarter ended June 30, 2022. |
SNOA Price Returns
| 1-mo | -37.92% |
| 3-mo | -40.57% |
| 6-mo | -50.00% |
| 1-year | -64.32% |
| 3-year | -59.27% |
| 5-year | -96.30% |
| YTD | -63.38% |
| 2021 | -37.19% |
| 2020 | 66.51% |
| 2019 | -31.77% |
| 2018 | -86.97% |
| 2017 | 8.13% |
Continue Researching SNOA
Want to see what other sources are saying about Sonoma Pharmaceuticals Inc's financials and stock price? Try the links below:Sonoma Pharmaceuticals Inc (SNOA) Stock Price | Nasdaq
Sonoma Pharmaceuticals Inc (SNOA) Stock Quote, History and News - Yahoo Finance
Sonoma Pharmaceuticals Inc (SNOA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...